Shijiazhuang Sihua Pharmaceutical Group’s Bosun Medical Devices: Simultaneously Empowering Industrial Optimization, Intelligent Upgrading, and Green Development


Category:

发布时间:2022-09-03

【概要描述】 Currently, driven by the rapid advancement of Internet, information technology, and automation, the production of pharmaceutical packaging materials is undergoing an upgrade toward greater automation and intelligence. As a domestic enterprise specializing in the R&D, manufacturing, and sales of innovative medical packaging materials, Shijiazhuang Sihua Pharmaceutical Group Jiangsu Bosheng Medical New Materials Co., Ltd. (Bosheng Medical Materials; stock code: 873710) is actively transitioning from traditional manufacturing to “intelligent manufacturing.”
With the continuous advancement of global pharmaceutical development, the related medical packaging materials industry is also experiencing robust growth. Preliminary estimates indicate that from 2015 to 2021, the global pharmaceutical packaging market expanded year by year, reaching a size of US$109.3 billion in 2021, with an average annual compound growth rate of 7.87%. This underscores the significant growth potential of the pharmaceutical packaging market.
Pharmaceutical packaging materials are a critical component that influences the final quality, stability, and safety of drug products. At present, China is continuously introducing and upgrading pharmaceutical packaging machinery and materials, which will usher in a new era for the pharmaceutical packaging industry.
 
Automation and Intelligence
Promote the optimization and upgrading of the industrial structure
 
Currently, driven by the rapid advancement of Internet, information technology, and automation, the production of pharmaceutical packaging materials is undergoing an upgrade toward greater automation and intelligence. As a domestic enterprise specializing in the R&D, manufacturing, and sales of innovative medical packaging materials, Shijiazhuang Sihua Pharmaceutical Group Jiangsu Bosheng Medical New Materials Co., Ltd. (Bosheng Medical Materials; stock code: 873710) is actively transitioning from traditional manufacturing to “intelligent manufacturing.”
Upon entering Bosheng Medical’s newly completed biomembrane production facility, one is immediately struck by the ubiquitous presence of state-of-the-art, fully automated and intelligent equipment. The facility features a unique dual-corridor layout: the outer corridor, designated as a visitor corridor, provides thermal insulation and serves as a barrier against mosquitoes and other insects, while the inner corridor, configured as a clean work area, effectively prevents cross-contamination. This high-standard design and construction ensure stringent product quality and support lean manufacturing practices.
According to staff, Bosheng Medical Devices operates the country’s first fully automated, specialized production line designed and manufactured in accordance with the structure of single-use systems (SUS) membranes used in bioprocessing. This custom-built line was tailored by the manufacturer to meet specific formulation requirements. It employs metering pumps to precisely deliver each layer of material, thereby ensuring uniform thickness across all layers and, consequently, overall membrane thickness uniformity.
Notably, the seven-layer co-extruded film’s product structure delivers physical properties—such as scratch resistance, puncture resistance, crush resistance, and weldability—that surpass those of imported films. Its overall performance is on par with any imported film, making it the “preferred choice” for domestic pharmaceutical companies seeking to replace imported materials with domestically produced alternatives.
Quality is both designed into and produced through manufacturing. For medical rubber stoppers and multilayer co-extruded films, the formulation is a critical determinant of product quality. At the same time, a superior formulation can only be translated into high-quality products when supported by stringent process control, reliable equipment, and robust testing capabilities. Leveraging years of technical expertise, Bosheng Medical Devices has independently developed and mastered a suite of high-performance formulations and production processes, thereby establishing the company’s proprietary core technologies—such as coated rubber stopper formulations and scalable manufacturing processes, as well as single-use multilayer co-extruded biomaterial film formulations and their large-scale production processes. The company places great emphasis on product technology and process innovation and will continue to increase R&D investment to sustain and enhance its competitive advantages in product technology, quality, and cost.
With the advancement of technology and the rapid development of China’s pharmaceutical industry, the pharmaceutical packaging sector has seen a growing array of new products and technologies. These include novel manufacturing processes and processing techniques; state-of-the-art production equipment and testing instruments; newly introduced or refined product standards and testing methods; significant research theories and academic achievements; as well as new certification and management systems—each of which plays a catalytic role in advancing the pharmaceutical and pharmaceutical packaging industries and driving their transformation and upgrading.
 
New Situation and New Momentum
Empowering the Green Development of the Packaging Materials Industry
 
Against the backdrop of increasingly stringent pharmaceutical quality regulation and growing public concern about drug safety, manufacturers of pharmaceutical rubber stoppers are likewise subject to tighter oversight and supervision by drug regulatory authorities and pharmaceutical manufacturers. At the same time, pharmaceutical companies are raising their quality requirements for pharmaceutical rubber stoppers, shifting their focus from low cost to high quality and high stability, and placing greater emphasis on whether the stoppers meet established standards for consistent quality and compatibility with the drug product when making procurement decisions.
After more than two decades of development and innovation, Bosheng Medical Devices has established itself as a leading benchmark in its specialized niche. The company is one of the five director units of the Pharmaceutical Rubber Stopper Special Committee of the China Association for Pharmaceutical Packaging, and has actively participated in drafting numerous association standards, including the “Good Manufacturing Practice for Pharmaceutical Rubber Stoppers,” the “Implementation Guide for Quality Audits of Pharmaceutical Rubber Stopper Suppliers,” and the “Guidance on Material Balance Accounting for Pharmaceutical Rubber Stoppers.” In 2016, the association standard “Guidance on Compatibility Studies Between Chemical Pharmaceuticals and Elastomeric Seals,” compiled under the company’s leadership, was adopted and refined by the Center for Drug Evaluation and officially promulgated in 2018. Subsequently, the National Medical Products Administration issued the Notice on the Release of the Technical Guidance Principles for Compatibility Studies Between Chemical Pharmaceuticals and Elastomeric Seals (Trial), marking another significant contribution by Bosheng to the advancement of the industry.
According to available information, Bosheng Medical Devices has taken the lead in establishing a domestic technological system for the development of pharmaceutical-grade rubber stoppers, thereby breaking the technological monopoly held by developed countries, enhancing the company’s independent innovation capabilities, and elevating the overall technological level of the domestic industry.
Through independent innovation, the company has taken the lead in China in mastering the patented vacuum deposition technology for poly-p-xylene coatings, overcoming key technical challenges such as the vacuum coating process for rubber stoppers, the adhesion between the coating and the stopper, and precise control of coating thickness. Leveraging the coating’s dense structure, chemical stability, and smooth surface properties, the company has successfully developed a series of coated rubber stoppers, further reducing contamination of pharmaceutical products and effectively addressing the issue of poor stability associated with conventional rubber stoppers when used with novel drugs.
In addition, Bosheng Medical Devices has pioneered the successful development of a new formulation and manufacturing process for cephalosporin-specific rubber stoppers in China, thereby filling a domestic gap; it is also the only company in the country to master the technology for producing radiation-resistant sterilizable rubber stoppers. Through proactive exploration of cutting-edge technologies and innovative approaches to the development of pharmaceutical packaging materials, Bosheng Medical Devices has, over more than two decades, served as an industry benchmark, making outstanding contributions to ensuring the efficacy and safety of medicines for the public and driving technological advancement and industrial growth in the pharmaceutical packaging sector.
Looking ahead, Bosheng Medical Devices will continuously monitor the competitive market environment and the regulatory authorities’ requirements for product quality and green development, strengthen research and development of critical core technologies, vigorously advance the R&D of innovative products, enhance the level of industrialization, sustain ongoing product development efforts, conduct trials with domestically produced raw materials, make process adjustments in response to customer needs, and ensure that product quality consistently meets both pharmaceutical regulatory standards and customer expectations, thereby maintaining the company’s market competitiveness.
 
Reprinted from: Pharmaceutical Economic Daily

Keywords: